Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words 'OZOLS RF' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 82 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Schilder, RJ; Gallo, JM; Millenson, MM; Bookman, MA; Weiner, LM; Rogatko, A; Rogers, B; Padavic-Shallers, K; Boente, M; Rosenblum, N; Adams, AL; Ciccotto, S; Ozols, RF
      Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, andtopotecan with peripheral-blood stem-cell support as front-line therapy

      JOURNAL OF CLINICAL ONCOLOGY
    2. Ozols, RF
      The current role of gemcitabine in ovarian cancer

      SEMINARS IN ONCOLOGY
    3. Ozols, RF
      Optimum chemotherapy for ovarian cancer

      INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
    4. Langer, CJ; McAleer, CA; Bonjo, CA; Litwin, S; Millenson, M; Kosierowski, R; Blankstein, K; Alexander, R; Ozols, RF
      Paclitaxel by 1-h infusion in combination with carboplatin in advanced non-small cell lung carcinoma (NSCLC)

      EUROPEAN JOURNAL OF CANCER
    5. Agus, DB; Bunn, PA; Franklin, W; Garcia, M; Ozols, RF
      HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer

      SEMINARS IN ONCOLOGY
    6. Ozols, RF
      Contemporary issues in the management of ovarian cancer

      SEMINARS IN ONCOLOGY
    7. Ozols, RF
      Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer

      SEMINARS IN ONCOLOGY
    8. Ozols, RF
      Management of advanced ovarian cancer consensus summary

      SEMINARS IN ONCOLOGY
    9. Ozols, RF
      The role of gemcitabine in the treatment of ovarian cancer

      SEMINARS IN ONCOLOGY
    10. Ozols, RF
      Ovarian cancer: Current status and future directions

      PROGRESS IN ANTI-CANCER CHEMOTHERAPY, VOL IV
    11. Ozols, RF
      Chemotherapy for ovarian cancer: Beyond paclitaxel plus carboplatin

      CANCER JOURNAL FROM SCIENTIFIC AMERICAN
    12. McGuire, WP; Brady, MF; Ozols, RF
      The Gynecologic Oncology Group experience in ovarian cancer

      ANNALS OF ONCOLOGY
    13. Ozols, RF; Gore, M; Trope, C; Grenman, S
      Intraperitoneal treatment and dose-intense therapy in ovarian cancer

      ANNALS OF ONCOLOGY
    14. Berek, JS; Bertelsen, K; du Bois, A; Brady, MF; Carmichael, J; Eisenhauer, EA; Gore, M; Grenman, S; Hamilton, TC; Hansen, SW; Harper, PG; Horvath, G; Kaye, SB; Luck, HJ; Lund, B; McGuire, WP; Neijt, JP; Ozols, RF; Parmar, MKB; Piccart-Gebhart, MJ; van Rijswijk, R; Rosenberg, P; Rustin, GJS; Sessa, C; Thigpen, JT; Trope, C; Tuxen, MK; Vergote, I; Vermorken, JB; Willemse, PHB
      Advanced epithelial ovarian cancer: 1998 consensus statements

      ANNALS OF ONCOLOGY
    15. Schilder, RJ; Johnson, S; Gallo, J; Kindsfather, S; Rogers, B; Bookman, MA; Millenson, MM; Boente, M; Rosenblum, N; Litwin, S; Ozols, RF
      Phase I trial of multiple cycles of high-dose chemotherapy supported by autologous peripheral-blood stem cells

      JOURNAL OF CLINICAL ONCOLOGY
    16. Ozols, RF
      Chemotherapy for ovarian cancer

      SEMINARS IN ONCOLOGY
    17. Langer, CJ; Gandara, DR; Calvert, P; Edelman, MJ; Ozols, RF
      Gemcitabine and carboplatin in combination: An update of phase I and phaseII studies in non-small cell lung cancer

      SEMINARS IN ONCOLOGY
    18. Ozols, RF
      Paclitaxel plus carboplatin in the treatment of ovarian cancer

      SEMINARS IN ONCOLOGY
    19. Ozols, RF
      Oral etoposide for the treatment of recurrent ovarian cancer

      DRUGS
    20. LANGER CJ; CALVERT P; OZOLS RF
      GEMCITABINE AND CARBOPLATIN IN COMBINATION - PHASE-I AND PHASE-II STUDIES

      Seminars in oncology
    21. MCGUIRE WP; OZOLS RF
      CHEMOTHERAPY OF ADVANCED OVARIAN-CANCER

      Seminars in oncology
    22. McGuire, WP; Ozols, RF
      Chemotherapy of advanced ovarian cancer (vol 25, pg 340, 1998)

      SEMINARS IN ONCOLOGY
    23. SHAPIRO JD; ROTHENBERG ML; SAROSY GA; STEINBERG SM; ADAMO DO; REED E; OZOLS RF; KOHN EC
      DOSE-INTENSIVE COMBINATION PLATINUM AND CYCLOPHOSPHAMIDE IN THE TREATMENT OF PATIENTS WITH ADVANCED UNTREATED EPITHELIAL OVARIAN-CANCER

      Cancer
    24. OZOLS RF
      CONTROVERSIES IN THE MANAGEMENT OF OVARIAN-CANCER

      International journal of gynecological cancer
    25. BOOKMAN MA; KLOTH DD; KOVER PE; SMOLINSKI S; OZOLS RF
      SHORT-COURSE INTRAVENOUS PROPHYLAXIS FOR PACLITAXEL-RELATED HYPERSENSITIVITY REACTIONS

      Annals of oncology
    26. OZOLS RF
      TREATMENT OF RECURRENT OVARIAN-CANCER - INCREASING OPTIONS - RECURRENT RESULTS

      Journal of clinical oncology
    27. OREILLY S; FLEMING GF; BAKER SD; WALCZAK JR; BOOKMAN MA; MCGUIRE WP; SCHILDER RJ; ALVAREZ RD; ARMSTRONG DK; HOROWITZ IR; OZOLS RF; ROWINSKY EK
      PHASE-I TRIAL AND PHARMACOLOGICAL TRIAL OF SEQUENCES OF PACLITAXEL AND TOPOTECAN IN PREVIOUSLY TREATED OVARIAN EPITHELIAL MALIGNANCIES - A GYNECOLOGIC-ONCOLOGY-GROUP STUDY

      Journal of clinical oncology
    28. BOOKMAN MA; KLOTH DD; KOVER PE; SMOLINSKI S; OZOLS RF
      INTRAVENOUS PROPHYLAXIS FOR PACLITAXEL-RELATED HYPERSENSITIVITY REACTIONS

      Seminars in oncology
    29. OZOLS RF
      FUTURE-DIRECTIONS IN THE CHEMOTHERAPY OF OVARIAN-CANCER

      Seminars in oncology
    30. OZOLS RF; VERMORKEN JB
      CHEMOTHERAPY OF ADVANCED OVARIAN-CANCER - CURRENT STATUS AND FUTURE-DIRECTIONS

      Seminars in oncology
    31. OZOLS RF
      GYNECOLOGIC-ONCOLOGY-GROUP TRIALS IN OVARIAN-CARCINOMA

      Seminars in oncology
    32. JOHNSON SW; LAUB PB; BEESLEY JS; OZOLS RF; HAMILTON TC
      INCREASED PLATINUM-DNA DAMAGE TOLERANCE IS ASSOCIATED WITH CISPLATIN RESISTANCE AND CROSS-RESISTANCE TO VARIOUS CHEMOTHERAPEUTIC-AGENTS IN UNRELATED HUMAN OVARIAN-CANCER CELL-LINES

      Cancer research
    33. OBASAJU CK; JOHNSON SW; ROGATKO A; KILPATRICK D; BRENNAN JM; HAMILTON TC; OZOLS RF; ODWYER PJ; GALLO JM
      EVALUATION OF CARBOPLATIN PHARMACOKINETICS IN THE ABSENCE AND PRESENCE OF PACLITAXEL

      Clinical cancer research
    34. OZOLS RF
      PACLITAXEL (TAXOL(R)) PLUS CARBOPLATIN AS FIRST-LINE TREATMENT FOR ADVANCED OVARIAN-CANCER

      International journal of gynecological cancer
    35. SCHRODER CP; GODWIN AK; ODWYER PJ; TEW KD; HAMILTON TC; OZOLS RF
      GLUTATHIONE AND DRUG-RESISTANCE

      Cancer investigation
    36. ESSAYAN DM; KAGEYSOBOTKA A; LICHTENSTEIN LM; COLARUSSO PJ; OZOLS RF; KING ED
      PACLITAXEL HYPERSENSITIVITY REVISITED

      Journal of clinical oncology
    37. BOOKMAN MA; OZOLS RF
      FACTORING OUTCOMES IN OVARIAN-CANCER

      Journal of clinical oncology
    38. ODWYER PJ; HAMILTON TC; LACRETA FP; GALLO JM; KILPATRICK D; HALBHERR T; BRENNAN J; BOOKMAN MA; HOFFMAN J; YOUNG RC; COMIS RL; OZOLS RF
      PHASE-I TRIAL OF BUTHIONINE SULFOXIMINE IN COMBINATION WITH MELPHALANIN PATIENTS WITH CANCER

      Journal of clinical oncology
    39. HAGEBOUTROS A; HUDES GR; BRENNAN J; GREEN F; HOFFMAN J; LACRETA FP; COLOFIORE J; MARTIN DS; OZOLS RF; ODWYER PJ
      PHASE-I TRIAL OF FLUOROURACIL MODULATION BY N-PHOSPHONACETYL-L-ASPARTATE AND 6-METHYLMERCAPTOPURINE RIBONUCLEOSIDE

      Cancer chemotherapy and pharmacology
    40. ESSAYAN DM; KAGEYSOBOTKA A; COLARUSSO PJ; LICHTENSTEIN LM; OZOLS RF; KING ED
      SUCCESSFUL PARENTERAL DESENSITIZATION TO PACLITAXEL

      Journal of allergy and clinical immunology
    41. JOHNSON SW; LISSY NA; MILLER PD; TESTA JR; OZOLS RF; HAMILTON TC
      IDENTIFICATION OF ZINC-FINGER MESSENGER-RNAS USING DOMAIN-SPECIFIC DIFFERENTIAL DISPLAY

      Analytical biochemistry
    42. ODWYER PJ; HAMILTON TC; YAO KS; TEW KD; OZOLS RF
      MODULATION OF GLUTATHIONE AND RELATED ENZYMES IN REVERSAL OF RESISTANCE TO ANTICANCER DRUGS

      Hematology/oncology clinics of North America
    43. OZOLS RF
      USA UPDATE ON PACLITAXEL IN OVARIAN-CANCER

      Annals of medicine
    44. LANGER CJ; LEIGHTON JC; COMIS RL; ODWYER PJ; MCALEER CA; BONJO CA; ENGSTROM PF; LITWIN S; OZOLS RF
      PACLITAXEL AND CARBOPLATIN IN COMBINATION IN THE TREATMENT OF ADVANCED NON-SMALL-CELL LUNG-CANCER - A PHASE-II TOXICITY, RESPONSE, AND SURVIVAL ANALYSIS

      Journal of clinical oncology
    45. HAGEBOUTROS A; ROGATKO A; NEWMAN EM; MCALEER C; BRENNAN J; LACRETA FP; HUDES GR; OZOLS RF; ODWYER PJ
      PHASE-I STUDY OF PHOSPHONACETYL-L-ASPARTATE, 5-FLUOROURACIL, AND LEUCOVORIN IN PATIENTS WITH ADVANCED CANCER

      Cancer chemotherapy and pharmacology
    46. HAAS NB; SCHILDER RJ; NASH S; WEINER LM; CATALANO RC; OZOLS RF; ODWYER PJ
      A PHASE-II TRIAL OF WEEKLY INFUSIONAL 5-FLUOROURACIL IN COMBINATION WITH LOW-DOSE LEUCOVORIN IN PATIENTS WITH ADVANCED COLORECTAL-CANCER

      Investigational new drugs
    47. HUDES GR; KOSIEROWSKI R; GREENBERG R; RAMSEY HE; FOX SC; OZOLS RF; MCALEER CA; GIANTONIO BJ
      PHASE-II STUDY OF TOPOTECAN IN METASTATIC HORMONE-REFRACTORY PROSTATE-CANCER

      Investigational new drugs
    48. OZOLS RF
      SURGICAL PALLIATION OF CANCER .11. GASTROINTESTINAL AND UROLOGIC CANCER - FOREWORD

      Current problems in cancer
    49. OZOLS RF
      BIOLOGIC TREATMENT OF HUMAN CANCER - FOREWORD

      Current problems in cancer
    50. OZOLS RF
      CLINICAL REVERSAL OF DRUG-RESISTANCE - FOREWORD

      Current problems in cancer
    51. OZOLS RF
      COMBINATION REGIMENS OF PACLITAXEL AND THE PLATINUM DRUGS AS FIRST-LINE REGIMENS FOR OVARIAN-CANCER

      Seminars in oncology
    52. KEARNS CM; BELANI CP; HAINSWORTH; ALBERTS DS; RAGHAVAN D; YOUNG RC; SHEA T; OZOLS RF
      PHARMACOKINETICS OF PACLITAXEL AND CARBOPLATIN IN COMBINATION - DISCUSSION

      Seminars in oncology
    53. OZOLS RF
      CURRENT STATUS OF CHEMOTHERAPY FOR OVARIAN-CANCER

      Seminars in oncology
    54. LANGER CJ; LEIGHTON JC; COMIS RL; ODWYER PJ; MCALEER CA; BONJO CA; ENGSTROM PF; LITWIN S; JOHNSON S; OZOLS RF
      PACLITAXEL BY 24- OR 1-HOUR INFUSION IN COMBINATION WITH CARBOPLATIN IN ADVANCED NONSMALL CELL LUNG-CANCER - THE FOX CHASE CANCER CENTER EXPERIENCE

      Seminars in oncology
    55. BUNN PA; ROWINSKY EK; KEARNS; RAGHAVAN; MUGGIA FM; CALVERT; CARNEY DN; BELANI CP; LANGER CJ; OZOLS RF; JOHNSON D; GIACCONE G; SHEA; GRECO FA; GELMON; HOFFMAN PC; CHOY H; AISNER J
      UNTITLED - DISCUSSION

      Seminars in oncology
    56. OZOLS RF
      CARBOPLATIN AND PACLITAXEL IN OVARIAN-CANCER

      Seminars in oncology
    57. GALLO JM; BRENNAN J; HAMILTON TC; HALBHERR T; LAUB PB; OZOLS RF; ODWYER PJ
      TIME-DEPENDENT PHARMACODYNAMIC MODELS IN CANCER-CHEMOTHERAPY - POPULATION PHARMACODYNAMIC MODEL FOR GLUTATHIONE DEPLETION FOLLOWING MODULATION BY BUTHIONINE SULFOXIMINE (BSO) IN A PHASE-I TRIAL OF MELPHALAN AND BSO

      Cancer research
    58. YAO KS; GODWIN AK; JOHNSON SW; OZOLS RF; ODWYER PJ; HAMILTON TC
      EVIDENCE FOR ALTERED REGULATION OF GAMMA-GLUTAMYLCYSTEINE SYNTHETASE GENE-EXPRESSION AMONG CISPLATIN-SENSITIVE AND CISPLATIN-RESISTANT HUMAN OVARIAN-CANCER CELL-LINES

      Cancer research
    59. SCHULTZ DC; VANDERVEER L; BUETOW KH; BOENTE MP; OZOLS RF; HAMILTON TC; GODWIN AK
      CHARACTERIZATION OF CHROMOSOME-9 IN HUMAN OVARIAN NEOPLASIA IDENTIFIES FREQUENT GENETIC IMBALANCE ON 9Q AND RARE ALTERATIONS INVOLVING 9P, INCLUDING CDKN2

      Cancer research
    60. OZOLS RF
      CARBOPLATIN AND PACLITAXEL (TAXOL(R)) FOR THE TREATMENT OF ADVANCED OVARIAN-CANCER

      International journal of gynecological cancer
    61. OZOLS RF
      TREATMENT OF OVARIAN-CANCER - CURRENT STATUS

      Seminars in oncology
    62. LACRETA FP; BRENNAN JM; HAMILTON TC; OZOLS RF; ODWYER PJ
      STEREOSELECTIVE PHARMACOKINETICS OF L-BUTHIONINE SR-SULFOXIMINE IN PATIENTS WITH CANCER

      Drug metabolism and disposition
    63. OZOLS RF
      RESEARCH DIRECTIONS IN EPITHELIAL OVARIAN-CANCER

      Gynecologic oncology
    64. HAAS NB; LACRETA FP; WALCZAK J; HUDES GR; BRENNAN JM; OZOLS RF; ODWYER PJ
      PHASE-I PHARMACOKINETIC STUDY OF TOPOTECAN BY 24-HOUR CONTINUOUS-INFUSION WEEKLY

      Cancer research
    65. SCHILDER RJ; LACRETA FP; PEREZ RP; JOHNSON SW; BRENNAN JM; ROGATKO A; NASH S; MCALEER C; HAMILTON TC; ROBY D; YOUNG RC; OZOLS RF; ODWYER PJ
      PHASE-I AND PHARMACOKINETIC STUDY OF ORMAPLATIN (TETRAPLATIN, NSC-363812) ADMINISTERED ON A DAY-1 AND DAY-8 SCHEDULE

      Cancer research
    66. JOHNSON SW; SWIGGARD PA; HANDEL LM; BRENNAN JM; GODWIN AK; OZOLS RF; HAMILTON TC
      RELATIONSHIP BETWEEN PLATINUM-DNA ADDUCT FORMATION AND REMOVAL AND CISPLATIN CYTOTOXICITY IN CISPLATIN-SENSITIVE AND CISPLATIN-RESISTANT HUMAN OVARIAN-CANCER CELLS

      Cancer research
    67. CORN BW; LANCIANO RM; BOENTE M; HUNTER WM; LADAZACK J; OZOLS RF
      RECURRENT OVARIAN-CANCER - EFFECTIVE RADIOTHERAPEUTIC PALLIATION AFTER CHEMOTHERAPY FAILURE

      Cancer
    68. JOHNSON SW; PEREZ RP; GODWIN AK; YEUNG AT; HANDEL LM; OZOLS RF; HAMILTON TC
      ROLE OF PLATINUM-DNA ADDUCT FORMATION AND REMOVAL IN CISPLATIN RESISTANCE IN HUMAN OVARIAN-CANCER CELL-LINES

      Biochemical pharmacology
    69. GODWIN AK; VANDERVEER L; SCHULTZ DC; LYNCH HT; ALTOMARE DA; BUETOW KH; DALY M; GETTS LA; MASNY A; ROSENBLUM N; HOGAN M; OZOLS RF; HAMILTON TC
      A COMMON REGION OF DELETION ON CHROMOSOME 17Q IN BOTH SPORADIC AND FAMILIAL EPITHELIAL OVARIAN-TUMORS DISTAL TO BRCAI

      American journal of human genetics
    70. TJULANDIN SA; GARIN AM; MESCHERYAKOV AA; PEREVODCHIKOVA NI; GORBUNOVA VA; SOKOLOV AV; LJUBIMOVA NV; MIRONOVA GT; MOLCHANOV GV; OZOLS RF; HAMILTON JM
      CISPLATIN-ETOPOSIDE AND CARBOPLATIN-ETOPOSIDE INDUCTION CHEMOTHERAPY FOR GOOD-RISK PATIENTS WITH GERM-CELL TUMORS

      Annals of oncology
    71. OZOLS RF; THIGPEN JT; DAUPLAT J; COLOMBO N; PICCART MJ; BERTELSEN K; LEVIN L; LUND B
      DOSE INTENSITY

      Annals of oncology
    72. DEVRIES EGE; HAMILTON TC; LIND M; DAUPLAT J; NEIJT JP; OZOLS RF
      DRUG-RESISTANCE, SUPPORTIVE CARE AND DOSE INTENSITY

      Annals of oncology
    73. ALLEN DG; BAAK J; BELPOMME D; BEREK JS; BERTELSEN K; HUININK WWT; VANDERBURG MEL; CALVERT AH; CONTE PE; DAUPLAT J; EISENHAUER EA; FAVALLI G; HACKER NF; HAMILTON TC; HANSEN HH; HANSEN M; VANHOUWELINGEN HC; KAYE SB; LEVIN L; LUND B; NEIJT JP; OZOLS RF; PICCART MJ; RUSTIN GJS; SESSA C; SOUTTER WP; THIGPEN JT; TROPE C; VERMORKEN JB; DEVRIES EGE
      ADVANCED EPITHELIAL OVARIAN-CANCER - 1993 CONSENSUS STATEMENTS

      Annals of oncology
    74. REED E; JANIK J; BOOKMAN MA; ROTHENBERG M; SMITH J; YOUNG RC; OZOLS RF; VANDERMOLEN L; KOHN E; JACOB JL; CORNELISON TL
      HIGH-DOSE CARBOPLATIN AND RECOMBINANT GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR IN ADVANCED-STAGE RECURRENT OVARIAN-CANCER

      Journal of clinical oncology
    75. BRENNAN JM; ODWYER PJ; OZOLS RF; LACRETA FP
      HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC DETERMINATION OF THE S-DIASTEREOISOMERS AND R-DIASTEREOISOMERS OF L-BUTHIONINE (SR)-SULFOXIMINE IN HUMAN PLASMA AND URINE

      Journal of chromatography. Biomedical applications
    76. HAAS NB; HINES JB; HUDES GR; JOHNSTON N; OZOLS RF; ODWYER PJ
      PHASE-I TRIAL OF 5-FLUOROURACIL BY 24-HOUR INFUSION WEEKLY

      Investigational new drugs
    77. OZOLS RF; ODWYER PJ; HAMILTON TC
      CLINICAL REVERSAL OF DRUG-RESISTANCE IN OVARIAN-CANCER

      Gynecologic oncology
    78. LIDOR YJ; OBRIANT KC; XU FJ; HAMILTON TC; OZOLS RF; BAST RC
      ALKYLATING-AGENTS AND IMMUNOTOXINS EXERT SYNERGISTIC CYTOTOXIC ACTIVITY AGAINST OVARIAN-CANCER CELLS - MECHANISM OF ACTION

      The Journal of clinical investigation
    79. HAMAGUCHI K; GODWIN AK; YAKUSHIJI M; ODWYER PJ; OZOLS RF; HAMILTON TC
      CROSS-RESISTANCE TO DIVERSE DRUGS IS ASSOCIATED WITH PRIMARY CISPLATIN RESISTANCE IN OVARIAN-CANCER CELL-LINES

      Cancer research
    80. YAO KS; GODWIN AK; OZOLS RF; HAMILTON TC; ODWYER PJ
      VARIABLE BASE-LINE GAMMA-GLUTAMYLCYSTEINE SYNTHETASE MESSENGER-RNA EXPRESSION IN PERIPHERAL MONONUCLEAR-CELLS OF CANCER-PATIENTS, AND ITS INDUCTION BY BUTHIONINE SULFOXIMINE TREATMENT

      Cancer research
    81. OZOLS RF
      EPITHELIAL OVARIAN-CANCER - AN UPDATE

      Bulletin du cancer
    82. OZOLS RF
      OVARIAN-CANCER .2. TREATMENT

      Current problems in cancer


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 10/08/20 alle ore 16:59:24